Stage 4 Cancer Survivor Gains 40% Muscle Mass in Irish Trial

John Bradley thought surviving stage four prostate cancer would be the hard part, but the aftermath left him struggling in ways he never expected.

The 66-year-old from Kanturk, Ireland, completed 39 rounds of radiotherapy in 2022 and entered remission. But the hormone treatments required to fight his prostate cancer crashed his testosterone to zero, triggering a cascade of brutal side effects that left him barely recognizing himself.

"You're lethargic, you can't sleep properly, your concentration levels are zero," Bradley explained. Simple conversations became exhausting after two minutes, reading books felt impossible, and his mental health took a silent beating while he wondered what came next.

That's when his doctor recommended the LIAM Mc Trial, a pioneering cancer rehabilitation program at University College Cork. The 12-week program paired 56 men living with advanced prostate, bladder, and kidney cancers with specialist physiotherapists, nurses, dietitians, and psychological support twice weekly.

Three months after Bradley's radiotherapy ended, he joined the trial. Twelve weeks later, everything changed.

His muscle mass increased by 40%. His old self emerged from the fog of treatment side effects, and he went from operating at maybe 60% to feeling like he's back at 90%.

"I have my confidence back. I don't have pains. I can sleep fine. I'm good. I'm very good," Bradley said. Today, he swims and hits the gym regularly, a stark contrast to the depleted man who finished treatment feeling abandoned by the healthcare system.

Why This Inspires

The trial's success highlights a critical gap in cancer care that's finally being addressed. Researchers noted an "overwhelmingly positive response" from all 56 participants, who gained not just physical strength but confidence and hope from the small group setting and peer support.

The Irish Cancer Society just announced €100,000 in renewed funding to analyze the trial's findings more deeply and gather long-term data. The ultimate goal is making supportive rehabilitation a standard part of cancer aftercare across Ireland, not an optional extra that patients stumble upon by chance.

Associate Professor Jack Gleeson, who co-leads the trial, says the results have been overwhelming. The National Cancer Control Programme and Ireland's health service are now exploring how to implement this into routine care nationwide.

Bradley's message to other men finishing cancer treatment is simple but urgent: get active, build your strength, and don't wait for help to find you. "I would hate to think where I'd be today without the LIAM Mc," he said.

The trial won Survivorship Project of the Year at this year's Irish Cancer Society Research Awards, validating what Bradley already knew from living it: surviving cancer is just the beginning, and nobody should face what comes next alone.